Serum Levels of Fibroblast Growth Factor 19 Correlate with the Severity of Diarrhea and Independently from Intestinal Inflammation in Patients with Inflammatory Bowel Disease or Microscopic Colitis

• DOI: 10.5152/tjg.2021.20247
• Publication Date: 2021-06-24T08:35:57Z
• Authors: Ivan Lyutakov; Radislav Nakov; ; Hristo Valkov; ; Rositsa Vatcheva-...; ; Borislav Vladimirov; ; Plamen Penchev
• Keywords: Adult; Diarrhea; Male; Middle Aged; Colitis; Inflammatory Bowel Diseases; Severity of Illness Index; 3. Good health; Colitis, Microscopic; Fibroblast Growth Factors; Irritable Bowel Syndrome; Feces; 03 medical and health sciences; Cross-Sectional Studies; 0302 clinical medicine; Case-Control Studies; Chronic Disease; Humans; Female; Leukocyte L1 Antigen Complex; Biomarkers

In chronic diarrhea patients, massive over-reporting symptom-based criteria for functional bowel disorders are pitfalls. There is currently no objective biomarker that may provide a correct correlation with the severity of diarrhea. To clarify role fibroblast growth factor-19 (FGF-19) as measurements in comparison patientreported outcome, based on Bristol Stool Form (BSF) Scale.Consecutive 100 patients underwent standard investigations laboratory tests, fecal calprotectin (FC), endoscopy biopsies, and serum FGF-19. All 14 healthy controls completed diary recording, BSF, stool frequency.We found irritable syndrome (IBS-D) n = 21/23 (91%) reported high number BSF ≥6, compared to inflammatory diseases (IBD) 56/77 (72%) ≥ 6 (P .011). FGF-19 median levels were significantly lower Microscopic colitis (0.010 pg/mL) IBD (0.009 compare IBS-D (266.9 subjects (463 < .001). Strong inverse frequency/day index was (r -0.800, P .001; r -0.739, .001), independently from disease activity -0.718, -0.792, .001).Serum can become new evaluating objectively intestinal inflammation. FC predictive biomarkers organic cause